Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis.
Acute coronary syndrome
Colchicine
MACE
Myocardial infarction
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
27
05
2022
accepted:
16
12
2022
pubmed:
8
1
2023
medline:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
Colchicine, thought to exert its effect via reduction of inflammation, has recently been studied in patients following acute coronary syndromes (ACS). We performed a meta-analysis of all available randomized controlled trials (RCTs) in this high-risk cohort, evaluating efficacy and safety. MEDLINE, PubMed, EMBASE, clinical trial registries, and select conference proceedings were searched for RCTs comparing colchicine to placebo in patients following ACS. The primary outcome was trial-defined major adverse cardiovascular events (MACE). Secondary endpoints included stroke, myocardial infarction (MI), all-cause and cardiovascular death, and urgent revascularization. Analysis was performed at the longest available clinical follow-up. Two RCTs with a pooled sample size of 5540 patients with 2778 (50.1%) receiving colchicine and 2762 (49.9%) placebo were included. In order to maximize consistency, composite efficacy endpoints between trials were modified. Compared to placebo, patients receiving colchicine had reduction in study-defined composite endpoint (5.5% vs. 7.6%) OR 0.67 (95% CI 0.46-0.98, p = 0.04, I These data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.
Identifiants
pubmed: 36609745
doi: 10.1007/s40119-022-00298-y
pii: 10.1007/s40119-022-00298-y
pmc: PMC9986187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
171-181Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959–75.
doi: 10.1161/CIRCRESAHA.114.302782
pubmed: 24902978
pmcid: 4144436
Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.
doi: 10.1093/eurheartj/ehaa575
pubmed: 32860058
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–164.
doi: 10.1016/j.jacc.2012.07.013
pubmed: 23182125
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082.
pubmed: 29198432
Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16(9):435.
doi: 10.1007/s11883-014-0435-z
pubmed: 25037581
Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–71.
doi: 10.1016/j.atherosclerosis.2017.12.027
pubmed: 29352570
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.
doi: 10.1056/NEJMoa1912388
pubmed: 31733140
Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian cops randomized clinical trial. Circulation. 2020;142(20):1890–900.
doi: 10.1161/CIRCULATIONAHA.120.050771
pubmed: 32862667
Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132(15):1395–403.
doi: 10.1161/CIRCULATIONAHA.115.017611
pubmed: 26265659
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700.
doi: 10.1136/bmj.b2700
pubmed: 19622552
pmcid: 2714672
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 192859
Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28.
doi: 10.1186/s13075-020-2120-7
pubmed: 32054504
pmcid: 7020579
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–61.
doi: 10.1038/nature08938
pubmed: 20428172
pmcid: 2946640
Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE. 2010;5(7): e11765.
doi: 10.1371/journal.pone.0011765
pubmed: 20668705
pmcid: 2909263
Franzosi MG. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97(22):2202–12.
doi: 10.1161/01.CIR.97.22.2202
Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115(6):473–9.
doi: 10.1016/S0002-9343(03)00435-2
pubmed: 14563504
Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915–21.
doi: 10.1016/j.ijcard.2012.10.050
pubmed: 23168009
Safi S, Sethi NJ, Nielsen EE, Feinberg J, Jakobsen JC, Gluud C. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev. 2019;12:CD012484.
pubmed: 31845756
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260(14):2088–93.
doi: 10.1001/jama.1988.03410140100032
pubmed: 2901501
Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730–7.
doi: 10.1136/bmj.318.7200.1730
pubmed: 10381708
pmcid: 31101
Bangalore S, Makani H, Radford M, Thakur K, Toklu B, Katz SD, et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127(10):939–53.
doi: 10.1016/j.amjmed.2014.05.032
pubmed: 24927909
Kristensen AMD, Bovin A, Zwisler AD, Cerquira C, Torp-Pedersen C, Botker HE, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21(1):415.
doi: 10.1186/s13063-020-4214-6
pubmed: 32446298
pmcid: 7245032